General Information of the m6A Target Gene (ID: M6ATAR00775)
Target Name Suppressor of cytokine signaling 5 (SOCS5)
Synonyms
CIS6; CISH5; CISH6; KIAA0671; Suppressor of cytokine signaling 5; SOCS-5 ; Cytokine-inducible SH2 protein 6; CIS-6 ; Cytokine-inducible SH2-containing protein 5
    Click to Show/Hide
Gene Name SOCS5
Chromosomal Location 2p21
Function
SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. May be a substrate-recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Inhibits for instance EGF signaling by mediating the degradation of the EGF receptor/EGFR. Involved in the regulation of T-helper cell differentiation by inhibiting of the IL4 signaling pathway which promotes differentiation into the Th2 phenotype. Can also partially inhibit IL6 and LIF signaling.
    Click to Show/Hide
Gene ID 9655
Uniprot ID
SOCS5_HUMAN
HGNC ID
HGNC:16852
Ensembl Gene ID
ENSG00000171150.9
KEGG ID
hsa:9655
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
SOCS5 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 knock-down experiment revealed that expressions of SOCS family members SOCS1, SOCS2, SOCS4, Suppressor of cytokine signaling 5 (SOCS5), and SOCS6 were increased after METTL3 knock-down. It indicated that METTL3 is involved in the development of Graves' disease (GD) by inducing mRNA m6A methylation modification of SOCS family members.
Target Regulation Down regulation
Responsed Disease Graves disease ICD-11: 5A02.0
In-vitro Model PBMCs (Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral blood and identified as any blood cell with a round nucleus)
Thyrotoxicosis [ICD-11: 5A02]
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 knock-down experiment revealed that expressions of SOCS family members SOCS1, SOCS2, SOCS4, Suppressor of cytokine signaling 5 (SOCS5), and SOCS6 were increased after METTL3 knock-down. It indicated that METTL3 is involved in the development of Graves' disease (GD) by inducing mRNA m6A methylation modification of SOCS family members.
Responsed Disease Graves disease [ICD-11: 5A02.0]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
Target Regulation Down regulation
In-vitro Model PBMCs (Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral blood and identified as any blood cell with a round nucleus)
References
Ref 1 METTL3 Is Involved in the Development of Graves' Disease by Inducing SOCS mRNA m6A Modification. Front Endocrinol (Lausanne). 2021 Sep 20;12:666393. doi: 10.3389/fendo.2021.666393. eCollection 2021.